FLXN Flexion Therapeutics, Inc. Stock Quote

FLXN [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	-	EPS (ttm)	-2.62	Insider Own	2.70%	Shs Outstand	49.36M	Perf Week	8.05%
Market Cap	479.68M	Forward P/E	-	EPS next Y	-0.60	Insider Trans	-3.12%	Shs Float	46.06M	Perf Month	-20.61%
Income	-113.70M	PEG	-	EPS next Q	-0.51	Inst Own	97.69%	Short Float	16.82%	Perf Quarter	-22.31%
Sales	85.60M	P/S	5.60	EPS this Y	35.80%	Inst Trans	0.14%	Short Ratio	9.15	Perf Half Y	-17.25%
Book/sh	-0.34	P/B	-	EPS next Y	65.50%	ROA	-45.90%	Target Price	-	Perf Year	7.80%
Cash/sh	3.44	P/C	2.74	EPS next 5Y	20.00%	ROE	818.80%	52W Range	7.52 - 14.39	Perf YTD	-18.54%
Dividend	-	P/FCF	-	EPS past 5Y	-3.20%	ROI	-45.20%	52W High	-33.50%	Beta	1.48
Dividend %	-	Quick Ratio	3.80	Sales past 5Y	-	Gross Margin	77.50%	52W Low	27.26%	ATR	0.66
Employees	257	Current Ratio	4.10	Sales Q/Q	11.00%	Oper. Margin	-	RSI (14)	49.87	Volatility	7.97% 7.12%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	54.60%	Profit Margin	-	Rel Volume	2.57	Prev Close	9.40
Shortable	Yes	LT Debt/Eq	-	Earnings	Mar 10 AMC	Payout	-	Avg Volume	846.56K	Price	9.57
Recom	1.80	SMA20	3.26%	SMA50	-10.99%	SMA200	-18.01%	Volume	1,242,828	Change	1.81%

Apr-07-21

Resumed

RBC Capital Mkts

Outperform

$18

Aug-20-20

Initiated

Goldman

Neutral

$15

Jul-31-20

Initiated

Oppenheimer

Outperform

$19

Jul-29-20

Initiated

Credit Suisse

Outperform

$19

Jun-25-20

Initiated

H.C. Wainwright

Buy

$25

May-27-20

Initiated

Guggenheim

Buy

$20

Dec-27-19

Reiterated

The Benchmark Company

Buy

$19 → $25

Dec-05-19

Initiated

Craig Hallum

Buy

Nov-25-19

Initiated

BTIG Research

Buy

$27

May-09-19

Upgrade

The Benchmark Company

Hold → Buy

$19

Jan-04-19

Reiterated

Needham

Buy

$42 → $36

Jan-04-19

Downgrade

The Benchmark Company

Buy → Hold

Jun-28-18

Initiated

The Benchmark Company

Buy

$39

Oct-09-17

Reiterated

Needham

Buy

$36 → $42

Aug-24-17

Initiated

Northland Capital

Outperform

Dec-22-16

Initiated

Raymond James

Strong Buy

Sep-06-16

Resumed

Lake Street

Buy

$38

Jul-21-16

Initiated

Lake Street

Buy

$38

May-03-16

Resumed

Wells Fargo

Outperform

Nov-04-15

Initiated

Cantor Fitzgerald

Buy

Apr-14-21 03:52AM	Would Shareholders Who Purchased Flexion Therapeutics' (NASDAQ:FLXN) Stock Three Years Be Happy With The Share price Today? Simply Wall St.
Apr-13-21 04:01PM	Flexion Therapeutics Announces Preliminary First-Quarter 2021 Revenue and Provides Financial Guidance for 2021 GlobeNewswire +13.12%
Apr-12-21 11:12AM	The Dip in These 3 Stocks Is a Buying Opportunity, Say Analysts TipRanks
Apr-08-21 04:30PM	Flexion Therapeutics to Present at the Needham 20th Annual Virtual Healthcare Conference GlobeNewswire
Apr-02-21 04:30PM	Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-31-21 07:30AM	Flexion Therapeutics Announces First Patient Treated in FX301 Phase 1b Trial for Management of Post-Operative Pain GlobeNewswire
Mar-15-21 09:00AM	Flexion Therapeutics to Present at the Oppenheimer 31st Annual Virtual Healthcare Conference GlobeNewswire
Mar-11-21 05:00AM	Flexion Therapeutics Inc (FLXN) Q4 2020 Earnings Call Transcript Motley Fool
Mar-10-21 08:15PM	Flexion Therapeutics (FLXN) Reports Q4 Loss, Misses Revenue Estimates Zacks
04:22PM	Flexion Therapeutics: Q4 Earnings Insights Benzinga
04:01PM	Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2020 Financial Results GlobeNewswire
01:30PM	Flexion Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-05-21 04:30PM	Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-04-21 12:30PM	Will Flexion Therapeutics (FLXN) Report Negative Q4 Earnings? What You Should Know Zacks
Mar-03-21 04:30PM	Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2020 Financial Results on March 10, 2021 GlobeNewswire
Mar-01-21 12:58PM	Flexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patients After Musculoskeletal Surgery Benzinga
07:30AM	Flexion Therapeutics Announces FDA Clearance of Investigational New Drug Application for FX301, a Novel Formulation of a Locally Administered NaV1.7 Inhibitor for Post-Operative Pain GlobeNewswire
Feb-22-21 04:30PM	Flexion Therapeutics to Present at the 42nd Annual Raymond James Virtual Institutional Investors Conference GlobeNewswire
Feb-18-21 02:15PM	Flexion To Test Higher Dose Of FX201 Gene Therapy In Early-Stage Osteoarthritis Study Benzinga
07:30AM	Flexion Therapeutics to Advance Investigational Gene Therapy FX201 into High Dose Cohort of Phase 1 Clinical Trial in Knee Osteoarthritis and Expand Low and Mid Dose Treatment Groups GlobeNewswire
Feb-01-21 09:00AM	National Basketball Retired Players Association, Sheryl Swoopes and Flexion Therapeutics Announce Partnership to Raise Awareness of ZILRETTA® GlobeNewswire +6.41%
Jan-13-21 07:00AM	Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 Results GlobeNewswire
Jan-07-21 04:30PM	Flexion Therapeutics to Present at the ICR \| Westwicke Investment Conference GlobeNewswire
Dec-21-20 01:03AM	When Will Flexion Therapeutics, Inc. (NASDAQ:FLXN) Turn A Profit? Simply Wall St.
Dec-16-20 02:16PM	Is FLXN A Good Stock To Buy Now? Insider Monkey
Dec-07-20 04:30PM	Flexion Therapeutics to Present at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference GlobeNewswire -5.50%
Dec-04-20 04:30PM	Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-06-20 04:30PM	Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -7.16%
06:41AM	Analyst Estimates: Here's What Brokers Think Of Flexion Therapeutics, Inc. (NASDAQ:FLXN) After Its Third-Quarter Report Simply Wall St.
Nov-05-20 04:30PM	Flexion Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference GlobeNewswire -9.48%
08:04AM	Flexion Therapeutics' (NASDAQ:FLXN) Shareholders Are Down 46% On Their Shares Simply Wall St.
Nov-04-20 06:15PM	Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates Zacks +8.08%
04:33PM	Flexion Therapeutics: Q3 Earnings Insights Benzinga
04:01PM	Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights GlobeNewswire
Nov-02-20 11:28AM	Why Flexion Therapeutics (FLXN) Stock is a Compelling Investment Case Insider Monkey
Oct-29-20 04:30PM	Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020 GlobeNewswire
12:34PM	Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-13-20 06:59AM	Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million GlobeNewswire +13.86%
Oct-08-20 04:30PM	Flexion Therapeutics to Present at the 2020 Cell & Gene Virtual Meeting on the Mesa GlobeNewswire
Oct-05-20 09:00AM	Flexion Therapeutics Announces Podium Presentation of FX301 Preclinical Data at Virtual ANESTHESIOLOGY 2020 Meeting GlobeNewswire
Oct-02-20 04:30PM	Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
04:30PM	Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CoinDesk
Sep-21-20 08:37AM	Have Insiders Been Buying Flexion Therapeutics, Inc. (NASDAQ:FLXN) Shares? Simply Wall St. -7.60%
Sep-09-20 04:30PM	Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference GlobeNewswire
Sep-08-20 04:30PM	Flexion Therapeutics Announces Treatment of First Patient in Second Cohort of FX201 Phase 1 Dose-Escalation Trial GlobeNewswire
Sep-04-20 04:30PM	Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-03-20 04:30PM	Flexion Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference GlobeNewswire
Aug-20-20 09:51AM	Benzinga's Top Upgrades, Downgrades For August 20, 2020 Benzinga
Aug-19-20 09:00AM	Flexion Therapeutics Announces Appointment of Liz Kwo, MD, to its Board of Directors GlobeNewswire
Aug-07-20 04:30PM	Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
01:22PM	How Does Flexion Therapeutics' (NASDAQ:FLXN) CEO Pay Compare With Company Performance? Simply Wall St.
Aug-06-20 12:27PM	Analyzing Flexion Therapeutics's Unusual Options Activity Benzinga
Aug-05-20 07:05PM	Flexion Therapeutics (FLXN) Reports Q2 Loss, Misses Revenue Estimates Zacks -5.85%
04:01PM	Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights GlobeNewswire
Jul-30-20 04:30PM	Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020 GlobeNewswire
Jul-28-20 12:32PM	Will Flexion Therapeutics (FLXN) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-24-20 06:31AM	OK Boomer, Flexion Stock Is Made For You InvestorPlace
Jul-23-20 12:00PM	Flexion Therapeutics (FLXN) Is Up 9.84% in One Week: What You Should Know Zacks
Jul-15-20 09:56AM	Are Options Traders Betting on a Big Move in Flexion (FLXN) Stock? Zacks
Jul-14-20 06:59AM	Flexion Therapeutics Announces Preliminary Second-Quarter 2020 ZILRETTA® Net Sales GlobeNewswire +11.56%
Jul-08-20 12:00PM	Flexion Therapeutics (FLXN) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Jul-02-20 08:30AM	Flexion Therapeutics, Inc. (NASDAQ:FLXN): When Will It Breakeven? Simply Wall St.
Jun-27-20 01:20PM	Heres What Hedge Funds Think About Flexion Therapeutics Inc (FLXN) Insider Monkey
Jun-25-20 10:10AM	Benzinga's Top Upgrades, Downgrades For June 25, 2020 Benzinga +7.20%
Jun-16-20 04:30PM	Flexion Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference GlobeNewswire +6.43%
Jun-11-20 05:36PM	Edited Transcript of FLXN earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents -9.68%
10:23AM	Is Flexion Therapeutics (FLXN) a Smart Long-term Buy? Insider Monkey
May-28-20 09:13AM	Flexion (FLXN) Soars: Stock Adds 6.6% in Session Zacks +12.83%
May-21-20 12:02PM	Why Flexion Therapeutics Is Tumbling 10% Today Motley Fool -9.98%
07:30AM	Flexion Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
May-20-20 04:01PM	Flexion Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
May-14-20 09:27AM	How Flexion Therapeutics (FLXN) Stock Stands Out in a Strong Industry Zacks
May-13-20 05:00PM	Flexion Therapeutics to Present at the RBC Capital Markets 2020 Virtual Global Healthcare Conference GlobeNewswire
May-09-20 03:00PM	Flexion Therapeutics Inc (FLXN) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 04:01PM	Flexion Therapeutics Reports First-Quarter 2020 Financial Results and Recent Business Highlights GlobeNewswire +5.53%
May-05-20 09:00AM	Flexion Therapeutics Announces Virtual Poster Presentations for FX201, an Intra-Articular Gene Therapy Candidate for the Treatment of Osteoarthritis, at the American Society of Gene & Cell Therapy Annual Meeting GlobeNewswire +5.45%
May-01-20 09:00AM	Flexion Therapeutics Announces Publication of New Abstracts Accepted at Osteoarthritis Research Society International OARSI 2020 GlobeNewswire -9.77%
Apr-30-20 04:30PM	Flexion Therapeutics to Report First-Quarter 2020 Financial Results on May 7, 2020 GlobeNewswire
Apr-27-20 07:30AM	Flexion Therapeutics Announces Positive Preclinical Data Supporting Development of FX301, a Locally Administered Nav1.7 Inhibitor Product Candidate for Post-Operative Pain GlobeNewswire +9.16%
Apr-07-20 04:30PM	Flexion Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference GlobeNewswire
Apr-03-20 04:30PM	Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Apr-01-20 07:00AM	Flexion Therapeutics Announces ZILRETTA® License Agreement and Provides Business Update Amid Coronavirus Pandemic GlobeNewswire -10.93%
Mar-16-20 03:49PM	Edited Transcript of FLXN earnings conference call or presentation 12-Mar-20 8:30pm GMT Thomson Reuters StreetEvents -32.24%
Mar-14-20 08:55AM	Flexion Therapeutics, Inc. Just Released Its Full-Year Results And Analysts Are Updating Their Estimates Simply Wall St.
Mar-12-20 06:35PM	Flexion Therapeutics (FLXN) Reports Q4 Loss, Tops Revenue Estimates Zacks -17.55%
04:01PM	Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results GlobeNewswire
Mar-11-20 04:30PM	Flexion Therapeutics Names Melissa Layman Chief Commercial Officer GlobeNewswire -10.86%
Mar-06-20 04:30PM	Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-05-20 12:30PM	Will Flexion Therapeutics (FLXN) Report Negative Earnings Next Week? What You Should Know Zacks
Mar-04-20 04:30PM	Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2019 Financial Results on March 12, 2020 GlobeNewswire
Feb-24-20 04:30PM	Flexion Therapeutics to Present at the 41st Annual Raymond James Institutional Investors Conference GlobeNewswire -6.24%
Feb-20-20 12:31PM	Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks
07:12AM	Have Insiders Been Buying Flexion Therapeutics, Inc. (NASDAQ:FLXN) Shares? Simply Wall St.
Feb-07-20 04:30PM	Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jan-28-20 02:36PM	5 'Strong Buy' Biotech Stocks to Buy for 2020 Kiplinger
01:48PM	5 'Strong Buy' Biotech Stocks With Rapidly Approaching Catalysts Kiplinger
Jan-15-20 06:34AM	When Will Flexion Therapeutics, Inc. (NASDAQ:FLXN) Turn A Profit? Simply Wall St.
Jan-13-20 08:30AM	Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update GlobeNewswire
Jan-10-20 07:13AM	The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx Benzinga -10.48%
Jan-09-20 04:01PM	Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2019 Revenue and Initial Revenue Guidance for 2020 GlobeNewswire

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Layman Melissa	Chief Commercial Officer	Mar 15	Sale	11.80	4,520	53,336	103,956	Mar 16 05:11 PM
Layman Melissa	Chief Commercial Officer	Jan 28	Sale	12.55	2,624	32,931	88,376	Jan 29 08:19 PM
Muzikant Adam	Chief Business Officer	Jan 05	Sale	11.13	4,005	44,576	73,455	Jan 07 06:02 PM
KELLEY SCOTT	Chief Medical Officer	Jan 05	Sale	11.13	6,829	76,007	113,549	Jan 07 05:58 PM
Wentworth Kerry	Chief Regulatory Officer	Jan 05	Sale	11.13	6,829	76,007	113,767	Jan 07 05:56 PM
Willwerth Christina	Chief Strategy Officer	Jan 05	Sale	11.13	6,602	73,480	115,186	Jan 07 05:55 PM
Levine Mark S.	General Counsel	Jan 05	Sale	11.13	6,829	76,007	107,431	Jan 07 05:52 PM
Arkowitz David	Chief Financial Officer	Jan 05	Sale	11.13	6,073	67,592	151,048	Jan 07 05:50 PM
MILINAZZO ALAN	Director	Jul 09	Option Exercise	2.20	18,450	40,500	22,950	Jul 10 04:06 PM
Stejbach Mark	Director	May 26	Buy	9.75	2,051	19,997	2,051	May 27 04:14 PM
Clayman Michael D.	President and CEO	May 26	Buy	9.75	10,256	99,996	346,605	May 27 04:11 PM
Arkowitz David	Chief Financial Officer	May 07	Sale	10.88	2,413	26,253	117,068	May 11 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience